Epigenomics AG · GETTEX:ECX

Epigenomics — H1 2014 Earnings Presentation

15 slides from Epigenomics's earnings presentation, Aug 12, 2014

  1. Slide 1: 6-Month Financial & Operational Update

    6-Month Financial & Operational Update Conference Call August 12, 2014 www.epigenomics.com

  2. Slide 2: Safe Harbor

    Safe Harbor  Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation, statements containing the words “expects”, “future”, “potential” and words of similar import. Such forward-looking statements involve known and unknown risks, uncer

  3. Slide 3: Dial-in and Conference Call Details

    Dial-in and Conference Call Details  Presenters Dr. Thomas Taapken, CEO & CFO  Tuesday, August 12, 2014  Dial-in numbers for the conference call: D: +49 69 247 501 895 (3 p.m. CET) UK: +44 203 367 9216 (2 p.m. GMT) U.S.A.: +1 408 916 9838 (9 a.m. EST)  Access Code for the web presention Login: h

  4. Slide 4: Financial Update

    Financial Update Dr. Thomas Taapken (CEO / CFO) 4 | 12 nd August 2014

  5. Slide 5: Key Financial Figures – Income Statement & Cash Flow

    Key Financial Figures – Income Statement & Cash Flow in thousand EUR H1 2013 H1 2014 Change expect where indicated (unaudited) (unaudited) Revenue 698 812 + 114 Cost of sales -226 -365 - 139 Operating costs -4,313 -4,596 - 283 EBIT -3,319 -3,616 - 297 Net loss -3,354 -4,063 - 709 Weighted-average nu

  6. Slide 6: Key Financial Figures – Liquid Assets, Balance Sheet & Other

    Key Financial Figures – Liquid Assets, Balance Sheet & Other in thousand EUR Dec 31, 2013 June 30, 2014 Change expect where indicated (audited) (unaudited) Liquid assets (incl. marketable securities) 7,957 6,754 -1,203 Total equity 6,459 4,926 -1,533 Total assets 11,081 9,928 -1,153 Share price in E

  7. Slide 7: Financial Outlook 2014

    Financial Outlook 2014  Earnings prognosis for 2014 remains unaltered, as the original guidance did not include any significant product revenues from the U.S. market  Revenue for FY 2014 expected to slightly increase from 2013 level  EBIT expected to be at a slightly lower level compared to 2013

  8. Slide 8: Operational Update

    Operational Update 8 | 12 nd August 2014

  9. Slide 9: Regulatory Status of Epi proColon®

    Regulatory Status of Epi proColon® Europe:  Commercially available since 2012 – growing sales but at low levels since no active commercial effort underway for the time being China:  BioChain filed for market approval of Epi proColon® with China Food and Drug Administration (CFDA) in April 2014 U.S

  10. Slide 10: Additional Clinical Study for Epi proColon® in the U.S.

    Additional Clinical Study for Epi proColon® in the U.S. Study to demonstrate increased participation in CRC screening in patients being offered Epi proColon® blood-based test vs. FIT stool-based test • In agreement with the FDA, the study: • will include patients actively managed by CRC screening pr

  11. Slide 11: Joint Commercialization Agreement with Polymedco for the U.S.A.

    Joint Commercialization Agreement with Polymedco for the U.S.A.  Polymedco U.S. market leader in the CRC screening field - more than $50m in test sales  Polymedco is ideally positioned (CRC focus) to address 1500+ existing LAB customers  Epigenomics to transfer product at cost to Polymedco, gross

  12. Slide 12: Three Pillars of U.S. Market Penetration

    Three Pillars of U.S. Market Penetration Commercial Reimbursement Guidelines expert groups / months First 6 LDT to IVD switch health economic data medical societies months 6-18 early adopters reimbursement KOL studies Polymedco customer months governmental support guidelines inclusion >18 base  Exp

  13. Slide 13: Summary & Outlook

    Summary & Outlook 13 | 12 nd August 2014

  14. Slide 14: Summary

    Summary Financial update  Revenue growth driven by Epi proColon® sales H1: +16%  2014 cash consumption estimated at around EUR 7m - 8m – currently funded until Q1 2015 Commercial activities  Increasing sales demonstrate growing acceptance of Septin9 in the market  BioChain submitted to CFDA in A

  15. Slide 15: Thank you for your attention!

    Thank you for your attention! Contact Investor Relations TICKER Europe U.S.A. Bloomberg: ECX:GR Antje Zeise Lauren Kwiecinski Reuters: EXXG.DE Manager Investor Relations Senior Associate Thomson ONE: ECX-XE Epigenomics AG The Trout Group LLC T. +49 30 24345 0 T. +1 646 378 2934 ADR OTC: EPGNY ir@epi

Epigenomics — H1 2014 Earnings Presentation on 6ix